Mosapride/rebamipide - IlDong Pharmaceutical

Drug Profile

Mosapride/rebamipide - IlDong Pharmaceutical

Alternative Names: Motireb; Motireb - IlDong pharmaceuticals; Rebamipide/mosapride

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ildong Pharmaceutical
  • Class Antiulcers; Gastrokinetics; Morpholines; Small molecules
  • Mechanism of Action Mucin stimulants; Oxygen radical formation antagonists; Prostaglandin agonists; Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyspepsia

Most Recent Events

  • 07 Sep 2016 Chemical structure information added
  • 01 Apr 2016 Phase-III clinical trials in Dyspepsia in South Korea (PO) (NCT02831543)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top